McCartney N, Oldridge N B, Hicks A, Jones N L
Department of Physical Education, McMaster University, Hamilton, Ontario, Canada.
Med Sci Sports Exerc. 1989 Jun;21(3):313-8.
We assessed the utility of short-term (30 s) maximal isokinetic cycle ergometry as an additional method of investigating the limitations to exercise in 33 carefully selected patients with documented coronary artery disease. The technique proved safe and reproducible in these patients. In relation to normal standards, performance was better in the maximal isokinetic cycle ergometer test (peak power = 819 +/- 116 W; average power = 532 +/- 72 W; total work = 13.1 +/- 2.1 kJ; 95-101% of predicted) than in the progressive incremental exercise test (VO2 = 1.80 +/- 0.37 l.min-1; power output = 919 +/- 165 kpm.min-1; 70-80% of predicted). Beta blockade did not affect maximal performance during either isokinetic or progressive incremental cycling, although maximal heart rate was significantly lower during both tests in patients on beta blockade. Power output in the progressive exercise was not as strongly related to the indices measured during the 30 s isokinetic test (r = 0.59-0.63) as it was in previous studies of healthy individuals (r = 0.89). The ability to detect individual variations in short-term exercise capacity measured with maximal isokinetic cycle ergometry may have significant potential value 1) as an additional method of determining the limitations to exercise and 2) when executing an exercise prescription in patients with coronary artery disease.
我们评估了短期（30秒）最大等速自行车测力计运动作为另一种研究33例经记录确诊为冠状动脉疾病的精心挑选患者运动受限情况的方法的效用。该技术在这些患者中被证明是安全且可重复的。与正常标准相比，最大等速自行车测力计测试中的表现（峰值功率 = 819 ± 116瓦；平均功率 = 532 ± 72瓦；总功 = 13.1 ± 2.1千焦；为预测值的95 - 101%）优于递增运动测试（VO2 = 1.80 ± 0.37升·分钟-1；功率输出 = 919 ± 165千帕·分钟-1；为预测值的70 - 80%）。β受体阻滞剂在等速或递增运动测试期间均未影响最大运动表现，尽管在接受β受体阻滞剂治疗的患者中，两项测试期间的最大心率均显著降低。递增运动中的功率输出与30秒等速测试期间测量的指标的相关性（r = 0.59 - 0.63）不如先前对健康个体的研究中那样强（r = 0.89）。用最大等速自行车测力计测量短期运动能力时检测个体差异的能力可能具有重大潜在价值：1）作为确定运动受限情况的另一种方法；2）在为冠状动脉疾病患者制定运动处方时。
